Objective-Endothelial cell activation drives early atherosclerotic plaque formation. Both fibronectin deposition and accumulation of oxidized low-density lipoprotein (oxLDL) occur early during atherogenesis, and both are implicated in enhanced endothelial cell activation. However, interplay between these responses has not been established. The objective of our study was to determine whether endothelial matrix composition modulates the inflammatory properties of oxLDL. Approach and Results-We now show that oxLDL-induced nuclear factor-κB activation, proinflammatory gene expression, and monocyte binding are significantly enhanced when endothelial cells are attached to fibronectin compared with basement membrane proteins. This enhanced response does not result from altered oxLDL receptor expression, oxLDL uptake, or reactive oxygen species production, but results from oxLDL-induced activation of the fibronectin-binding integrin α5β1. Preventing α5β1 signaling (blocking antibodies, knockout cells) inhibits oxLDL-induced nuclear factor-κB activation and vascular cell adhesion molecule-1 expression. Furthermore, oxLDL drives α5β1-dependent integrin signaling through the focal adhesion kinase pathway, and focal adhesion kinase inhibition (PF-573228, small interfering RNA) blunts oxLDL-induced nuclear factor-κB activation, vascular cell adhesion molecule-1 expression, and monocyte adhesion. Last, treatment with the α5β1 signaling inhibitor, ATN-161, significantly blunts atherosclerotic plaque development in apolipoprotein E-deficient mice, characterized by reduced vascular cell adhesion molecule-1 expression and macrophage accumulation without affecting fibrous cap size. Conclusions-Our data suggest that α5β1-mediated cross-talk between fibronectin and oxLDL regulates inflammation in early atherogenesis and that therapeutics that inhibit α5 integrins may reduce inflammation without adversely affecting plaque structure. (Arterioscler Thromb Vasc Biol. 2014;34:1362-1373.) (A.P.M.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
H ypercholesterolemia, an increase in circulating cholesterol, remains the most recognized atherogenic risk factor, with genetic and epidemiological studies linking lowdensity lipoproteins (LDLs) to atherosclerosis. 1 While native LDL acts benignly on vascular pathology, post-translational modifications such as oxidation and glycation enhance the atherogenic nature of LDL. Modified LDL exhibits reduced LDL receptor affinity and enhanced uptake by scavenger receptors (ie, CD36 and the lectin-like oxidized LDL [oxLDL] receptor 1). Although the role of oxLDL in atherosclerosis has yet to be definitively proven, multiple lines of evidence suggest that oxLDL contributes to endothelial cell activation, a phenotypic conversion characterized by enhanced permeability and proinflammatory gene expression. Although early reports failed to show oxLDL-induced proinflammatory gene expression in endothelial cells, 2 subsequent studies demonstrated that oxLDL stimulates vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) expression to facilitate leukocyte adhesion. 3, 4 Apolipoprotein E-deficient (ApoE −/− ) mice lacking the endothelial oxLDL receptor 1 exhibit reduced plaque size, 5 whereas enhancing endothelial oxLDL receptor 1 expression exacerbates atherosclerotic plaque development. 6 Current data from both cell culture and animal models suggest that extracellular matrix remodeling regulates endothelial cell activation. Although the macrovasculature is largely devoid of fibronectin under healthy conditions, 7, 8 the subendothelial basement membrane remodels into a fibronectinrich matrix simultaneously with enhanced endothelial cell proinflammatory gene expression during early atherogenesis. Endothelial cells interacting with fibronectin show augmented inflammatory responses to shear stress, 7, 9 and limiting fibronectin deposition in atheroprone mice either genetically or with peptide inhibitors blunts both inflammation and early atherosclerotic plaque formation. 8, 10 OxLDL promotes matrix remodeling during multiple pathological conditions 11, 12 ; however, much less is known about how matrix composition affects the cellular response to oxLDL.
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Early studies found that minimally modified LDL could activate endothelial β1 integrins to promote apical fibronectin deposition. 13 This apical fibronectin deposition was suggested to facilitate monocyte attachment directly through fibronectin interactions with the leukocyte integrin α4β1. However, it was later shown that α4β1 interactions with fibronectin play a minor role in leukocyte adhesion to the atherosclerotic endothelium compared with the canonical α4β1 ligand VCAM-1. 14 We previously found that adhesion to a fibronectin matrix significantly enhances oxLDL-induced endothelial cell permeability, 15 suggesting that fibronectin deposition may alter the cellular response to oxLDL. Therefore, we sought to determine whether matrix composition affects oxLDL-induced endothelial cell inflammatory response.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Leukocyte interactions with the endothelium represent a critical and tightly regulated process in the inflammatory response. To assess the role of cell-matrix interactions in oxLDL-induced inflammation, we compared oxLDL-induced monocyte binding in human aortic endothelial cells plated on either basement membrane proteins or fibronectin. Although oxLDL treatment did not stimulate attachment of primary human monocytes or THP-1 monocytes in endothelial cells on basement membrane proteins ( Figure 1A and Figure I in the online-only Data Supplement), endothelial cells on fibronectin showed a nearly 2-fold increase in monocyte attachment, suggesting that fibronectin augments oxLDL's inflammatory properties. Given the importance of endothelial ICAM-1 and VCAM-1 for monocyte adhesion, we next tested whether matrix composition affects their expression after oxLDL treatment. Treatment with 100 μg/mL oxLDL induced a rapid and transient increase in VCAM-1 mRNA ( Figure 1B) , whereas ICAM-1 mRNA expression was delayed but sustained ( Figure 1C ). Consistent with the monocyte adhesion data, endothelial cells on fibronectin show greater VCAM-1 and ICAM-1 expression at both the mRNA ( Figure 1B and 1C) and protein ( Figure 1D -1F) levels. Native LDL did not induce VCAM-1 expression, suggesting that these effects are specific to oxLDL (Figure II in the online-only Data Supplement). Importantly, the oxLDL used in these studies contained <10 pg/mL of endotoxin ( Figure  III in the online-only Data Supplement), which is 4 orders of magnitude below the threshold for endotoxin-induced ICAM-1/VCAM-1 expression (100 ng/mL; Figure III in the online-only Data Supplement). Although high concentrations of oxLDL can stimulate endothelial cell apoptosis, treatment with 100 μg/mL of oxLDL did not induce endothelial cell apoptosis as assessed by annexin V binding and analysis of cleaved caspase 3 and poly ADP ribose polymerase ( Figure IV in the online-only Data Supplement).
The transcription factor nuclear factor-κB (NF-κB) regulates the expression of proinflammatory genes, such as ICAM-1 and VCAM-1. 16 NF-κB-dependent transcription requires both nuclear translocation of the p65 subunit (hereafter referred to as NF-κB) and NF-κB phosphorylation on serine 536 in the transactivation domain. 16 Therefore, we next tested whether matrix composition affects oxLDL-induced proinflammatory signaling by assessing NF-κB phosphorylation and nuclear translocation. Endothelial cells on fibronectin showed enhanced oxLDL-induced NF-κB phosphorylation ( Figure 2A ) and nuclear translocation ( Figure 2B ) compared with cells on basement membrane proteins. Consistent with NF-κB-driven expression, inhibiting NF-κB with either a pharmacological inhibitor (BAY 11-7082; Figure 2C ) or a dominant-negative inhibitor of κB construct (super-repressor inhibitor of κB; Figure 2D ) significantly blunted oxLDLinduced VCAM-1 expression. Taken together, these results suggest that matrix composition affects the ability of oxLDL to activate NF-κB-dependent transcription of proinflammatory genes.
Adhesion to fibronectin could enhance oxLDL's proinflammatory response by altering the expression of oxLDL receptors, affecting oxLDL uptake, or modifying oxLDL-induced signaling, such as reactive oxygen species (ROS) production. However, fluorescence-activated cell sorting analysis of the endothelial oxLDL receptors oxLDL receptor 1, tolllike receptor 4, and CD36 showed no difference in the surface expression in response to matrix composition ( Figure  V in the online-only Data Supplement). Matrix composition also failed to affect uptake of Dil-labeled oxLDL ( Figure  V in the online-only Data Supplement). Because oxLDLinduced inflammation requires ROS in multiple cell types, 17 we next tested for matrix-dependent ROS production after oxLDL treatment. Human aortic endothelial cells on either basement membrane or fibronectin were pretreated with with 2′,7′-dichlorofluorescein diacetate, a redox-sensitive fluorogenic dye, and then treated with oxLDL. Like receptor expression and function, oxLDL-induced ROS production did not differ based on matrix composition ( Figure V Previous reports suggest that oxLDL can activate endothelial β1 integrins, 13 presumably α5β1, the main fibronectinbinding integrin in endothelial cells. Because oxLDL-induced α5β1 integrin signaling could contribute to the altered NF-κB activation observed, we next tested whether oxLDL could stimulate α5β1 activation and α5β1-dependent signaling. To measure α5β1 activation, we used an α5β1-specific ligand mimetic consisting of a glutathione S-transferase fusion protein containing the 9th to 11th fibronectin type III repeats (GST-FNIII 9-11 ) as previously described. 18 Treatment with oxLDL enhanced GST-FNIII 9-11 retention ( Figure 3A) without affecting α5 surface expression ( Figure 3B ), consistent with enhanced α5β1 integrin activation. To test whether subsequent α5β1 ligation is required for oxLDL-induced VCAM-1 expression, we used blocking antibodies either to the integrin binding site in fibronectin (16G3) or to the α5β1 integrin (P1D6, SNAKA52). Blocking either fibronectin with 16G3 ( Figure 3C ) or the α5β1 integrin with P1D6 or SNAKA52 ( Figure 3D ) significantly blunted oxLDL-induced VCAM-1 expression. Control antibodies that bind to fibronectin but do not inhibit integrin binding (11E5) or that bind to other fibronectin-binding integrins such as αvβ3 (LM609) and αvβ5 (P1F6) did not affect oxLDL-induced VCAM-1 expression. Consistent with these findings, the α5-blocking antibodies also prevented oxLDL-induced NF-κB activation, whereas αvβ3 and αvβ5 blocking antibodies did not ( Figure 3E ).
To verify the significance of integrin α5 in oxLDL-induced (VCAM-1) and nuclear factor-κB (NF-κB) activation. A, Human aortic endothelial cells (HAECs) were treated with oxLDL (100 μg/mL) for the indicated times. Immunoblotting was performed for phospho-FAK Y397, Y576, Y577, total FAK, and extracellular signal-regulated kinase (ERK). Representative images are shown (n=4). B, HAECs pretreated with blocking antibodies to α5 (P1D6, SNAKA52), αvβ3 (LM609), or αvβ5 (P1F6) were treated with oxLDL for 1 hour. Immunoblotting was performed for phospho-FAK Y397 and ERK. Representative images are shown (n=3). C, HAECs were pretreated with PF-573228 (10 μmol/L; 1 hour) and treated with oxLDL for indicated times. Immunoblotting was performed for phospho-FAK Y397, phospho-NF-κB (P-NF-κB), and ERK (n=4). D, HAECs pretreated with PF-573228 were treated with oxLDL for 6 hours, and VCAM-1 expression was determined by Western blotting. Representative images are shown (n=3). E, HAECs were transfected with anti-FAK small interfering RNA (siRNA) and treated for the indicated times. Immunoblotting was performed for FAK, P-NF-κB, and β-tubulin. Representative images are shown (n=4). F, HAECs were transfected with anti-FAK siRNA and then treated with oxLDL for 6 hours. Immunoblotting was performed for FAK, VCAM-1, and ERK. Representative images are shown (n=4). Values are means±SE. *P<0.05 compared with no treatment condition. #P<0.05 comparing treatment conditions. NT indicates no treatment.
inflammation, we isolated mouse aortic endothelial cells from mice expressing a floxed α5 integrin allele (gift of Richard Hynes, Massachusetts Institute of Technology). After Cremediated excision of the α5 gene, oxLDL-induced VCAM-1 expression was significantly reduced ( Figure 3F ). Together, these data suggest that α5β1 integrin activation plays a critical role in oxLDL-induced inflammation.
Because our data demonstrate a crucial role for α5 in oxLDL-induced inflammation, we next investigated the role of focal adhesion kinase (FAK), a common integrin signaling partner. 19 OxLDL stimulated a rapid increase in FAK phosphorylation at the autophosphorylation site (Tyr397) and in the kinase domain (Tyr576, Tyr577) required for full FAK kinase activity ( Figure 4A ). Consistent with the role of α5β1 activation, FAK stimulation by oxLDL was completely inhibited by the α5β1-blocking antibodies P1D6 and SNAKA52 but not by the αvβ3-blocking antibody LM609 and the αvβ5blocking antibody P1F6 ( Figure 4B ). The ATP-competitive FAK inhibitor, PF-573228, significantly repressed oxLDLinduced NF-κB activation ( Figure 4C ), VCAM-1 expression ( Figure 4D ), and monocyte adhesion ( Figure VI Because α5 signaling contributes to oxLDL-induced inflammation, we next tested whether inhibiting α5 signaling in vivo was sufficient to reduce atherosclerosis in hypercholesterolemic mice. Male, 8-to 10-week-old ApoE −/− mice were fed a high-fat Western diet for 8 weeks to induce atherosclerosis. On initiation of Western-diet feeding, mice were treated with either saline or the α5 signaling inhibitor ATN-161, a peptide mimetic of the PHSRN sequence of fibronectin, 20 for the entire 8-week feeding regimen. ATN-161 was administered intraperitoneally at 5 mg/kg 3 times a week, consistent with previously published efficacy reports in murine cancer models. 21, 22 Treatment with the ATN-161 peptide did not affect mouse weight or blood glucose, total cholesterol, high-density lipoprotein cholesterol, LDL cholesterol, or triglyceride levels ( Figure VIII (Figure 5A and 5B) . Analysis of plaque cross sections using MOVAT staining showed a ≈40% reduction in plaque size in the aortic root ( Figure 5C and 5D ) and a ≈60% reduction in the carotid sinus ( Figure IX Although deletion of plasma fibronectin was previously shown to reduce plaque size and macrophage content, 8 the smooth muscle-rich fibrous cap was similarly ablated, suggesting that targeting this pathway could lead to the formation of vulnerable plaques prone to rupture. To assess whether α5 inhibitors similarly affect plaque composition, we analyzed macrophage (Mac2-positive) and smooth muscle (smooth muscle actin positive) content of these plaques in the aortic root ( Figure 6A ). The number of plaques per section of the aortic root was similar between saline-and ATN-161-treated groups ( Figure 6B ), suggesting that ATN-161 reduces plaque area by limiting plaque size. ATN-161 treatment reduced the Mac2positive regions in the aortic root and carotid sinus by 65% and 75%, respectively, indicative of diminished macrophage levels ( Figure 6C ; Figure IX in the online-only Data Supplement). Although smooth muscle actin-positive smooth muscle staining showed a trend toward lower levels ( Figure 6D ), this effect was not statistically significant. Furthermore, the percent area of the plaque positive for smooth muscle actin ( Figure 6E ), the thickness of the fibrous caps when present ( Figure 6F) , and the percentage of plaques scored positive for smooth muscle actin-rich fibrous caps ( Figure 6G ) were all unaltered in the ATN-161-treated mice. These data demonstrate that integrin α5 signaling contributes to the development of atherosclerosis, and blocking integrin α5 function significantly reduces plaque size by diminishing macrophage levels without affecting early smooth muscle recruitment.
Discussion
Transition to a fibronectin-rich matrix occurs before inflammatory cell recruitment, and limiting fibronectin deposition in vivo inhibits atherosclerosis and neointimal hyperplasia. 7, 8, 10 OxLDL accumulates early in atherosclerosis and promotes endothelial cell activation. 15, 23 We demonstrate here that composition of the endothelial matrix modulates oxLDL-induced NF-κB activation, NF-κB-dependent proinflammatory gene expression (ICAM-1, VCAM-1), and monocyte attachment. This matrix-dependent response to oxLDL does not result from altered surface expression of oxLDL receptors, oxLDL uptake, or changes in ROS production. Instead, oxLDL treatment activates the fibronectin-binding integrin α5β1, and preventing α5β1 signaling (blocking antibodies, knockout cells) abolishes oxLDL-induced NF-κB activation and VCAM-1 expression. Both mouse and human atherosclerotic plaques show α5 expression in the endothelium and macrophages, and treating Western diet-fed ApoE knockout mice with the α5β1 signaling inhibitor, ATN-161, significantly reduces VCAM-1 expression, macrophage content, and atherosclerotic plaque size. Together, these data demonstrate that α5β1 integrin signaling critically regulates oxLDL-induced proinflammatory responses in early atherogenesis.
Despite nearly 30 years of study, several controversies still remain concerning the role of oxLDL in endothelial activation, including the presentation of oxLDL to endothelial cells, the degree of LDL oxidation, and the mechanism of oxLDL-induced inflammation. The predominant theory on LDL oxidation suggests that LDL becomes oxidized after accumulation in the intima. 24 Although this model might limit the potential for endothelial interaction with oxLDL, oxidation of the apoB 100 protein on LDL reduces its affinity for matrix, suggesting that it could diffuse to the endothelial surface. 25 Additionally, several recent studies have found a pool of electronegative LDL similar to highly oxLDL, termed L5, in human plasma. 26, 27 Early studies identified minimally modified LDL, but not highly oxLDL, as the predominant inflammatory species 28 and showed an important role for the oxidized phospholipid oxidized 1-palmitoyl-2-arachidonoylsn-glycero-3-phosphorylcholine (oxPAPC) in mediating this effect. 28, 29 These studies did not observe ICAM-1 or VCAM-1 expression by oxLDL, minimally modified LDL (MM-LDL), or oxPAPC. However, other groups have shown oxLDLinduced ICAM-1 and VCAM-1 expression in arterial endothelial cells. 3, 4 Consistent with this, highly electronegative L5 LDL (similar to highly oxLDL) from human plasma induces VCAM-1 expression in arterial endothelial cells. 26 Therefore, the endothelial cell inflammatory response to oxLDL likely differs based on the degree of LDL oxidation.
Vascular fibronectin deposition affects leukocyte recruitment in multiple ways. Published work and data presented herein show that fibronectin deposition into the subendothelial matrix affects the endothelial cell activation response to multiple stimuli. 7, 8, 10 However, apical deposition of fibronectin containing the alternatively spliced connecting segment (connecting segment 1) domain provides direct interaction sites for α4β1 integrins on leukocytes. 13 Although MM-LDL stimulates apical fibronectin deposition, subsequent ex vivo analysis demonstrate that only a minority (<25%) of monocyte interactions with atherosclerotic endothelial occur through apical connecting segment 1 fibronectin. 14 Interestingly, MM-LDLinduced apical fibronectin deposition is postulated to occur through α5β1 integrin activation, because MM-LDL enhances β1 integrin ligation and blocking α5β1 prevents monocyte binding to MM-LDL-stimulated endothelial cells. 13 However, maximal induction of monocyte binding with MM-LDL takes 4 hours, 13, 28 whereas α5β1 activation occurs rapidly ( Figure 3A ). Furthermore, cycloheximide treatment inhibits MM-LDL-induced monocyte binding, suggesting that new gene expression is required, 28 and MM-LDL does not affect α5β1 expression. 13 While data presented herein provide direct proof that oxLDL induces α5β1 activation, our work suggests that α5β1-dependent signaling after interaction with subendothelial fibronectin supports oxLDL-induced proinflammatory gene expression.
Although the redox-sensitive transcription factor NF-κB classically mediates proinflammatory ICAM-1 and VCAM-1 expression, there are conflicting reports as to NF-κB's role in oxLDL-induced endothelial inflammatory gene expression. 30, 31 Although macrophages stimulated with MM-LDL show enhanced NF-κB signaling, MM-LDL fails to activate NF-κB in endothelial cells. 31, 32 However, highly oxLDL promotes NF-κB activation in endothelial cells, smooth muscle cells, and fibroblasts, 30 and our data support an important role for NF-κB activation in matrix-specific VCAM-1 expression by oxLDL. Interestingly, oxLDL stimulates ROS production independent of matrix composition, suggesting that ROS production is insufficient to activate NF-κB. In our system, oxLDL activates NF-κB through an α5β1 integrin-dependent pathway requiring the tyrosine kinase FAK. Although multiple groups implicate FAK signaling in NF-κB activation and proinflammatory gene expression, 33, 34 the mechanisms by which oxLDL and α5β1-dependent FAK signaling converge to activate NF-κB remain unknown.
Although the integrin αvβ3 has received considerable attention in cardiovascular disease models, 35 much less is known about α5β1 integrins. Analysis of mRNA isolated from human plaques and abdominal aortic aneurysms shows enhanced α5 expression, 36, 37 whereas protein levels were shown to be enhanced after carotid injury and induced arteriogenesis. 38, 39 Immunohistochemistry from mouse and human plaques suggests that α5β1 expression occurs predominantly in the endothelial layer and plaque macrophages ( Figure VII in the online-only Data Supplement). Our data suggest that endothelial α5 integrins contribute to proinflammatory gene expression and monocyte recruitment. The α5 integrin inhibitor ATN-161, a derivative of the fibronectin synergy sequence known to bind specifically to α5, 40 significantly reduces VCAM-1 expression, macrophage content, and atherosclerotic plaque size in hypercholesterolemic mice. Although ATN-161 can interact with multiple integrin β subunits, 41, 42 ATN-161 has only been shown to inhibit α5β1 integrin signaling. [43] [44] [45] Although these data are consistent with a role for α5 in endothelial cell activation, ATN-161 treatment may limit plaque formation through effects on other cell types as well. Inhibiting α5β1 in plaque macrophages could influence macrophage migration, 46 phagocytosis, 47 and gene expression. 48 Future studies examining cell type-specific deletion of α5 integrins should shed further light into the cellular mechanisms underlying this therapeutic effect.
Matrix-specific integrin signaling may contribute to multiple processes during atherosclerotic plaque formation, including endothelial activation, fibrous cap formation, and plaque angiogenesis. 35 Several published studies suggest that limiting fibronectin deposition blunts early inflammation in the atherosclerotic plaque, 8, 10 and work from our group has shown that fibronectin enhances endothelial activation in response to multiple atherogenic stimuli. 7, 15, 49 While genetic deletion of plasma fibronectin reduces endothelial activation and plaque inflammation, 8 fibronectin deletion similarly reduced fibrous cap formation, suggesting that depleting fibronectin could destabilize the plaque promoting plaque rupture. 8 However, we show that inhibiting the fibronectin-binding integrin α5β1 similarly reduces plaque inflammation without affecting early smooth muscle recruitment ( Figures 5 and 6 ), potentially because of an important role for other fibronectin-binding integrins in smooth muscle growth and migration. Although other groups have shown an important role for α5β1 in smooth muscle growth and migration in cell culture models, 50 our current data suggest that α5β1 may show limited expression in the smooth muscle, at least at early stages of plaque development. Taken together, our data suggest that α5β1 integrin inhibitors, currently in clinical trials targeting cancer, could be redirected for use in atherosclerosis.
